One of these compounds, the angiotensin II receptor type 1 antagonist Losartan, was shown to efficiently prevent the pathogenic intra-CNS overproduction of TGF-beta 1 involved in post-stroke epilepsy [105] and in Alzheimer’s disease [106]. Here, AGTR1 is linked to early-onset autosomal dominant Alzheimer disease.